

# Franco Muggia

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7517788/franco-muggia-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14  
papers

227  
citations

8  
h-index

15  
g-index

15  
ext. papers

261  
ext. citations

4.7  
avg. IF

4.02  
L-index

#	Paper	IF	Citations
14	BRCAness and its implications for platinum action in gynecologic cancer. <i>Anticancer Research</i> , <b>2014</b> , 34, 551-6	2.3	48
13	Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). <i>Cancer</i> , <b>1982</b> , 49, 1555-60	6.4	23
12	Advanced ovarian cancer: three-year results of a 6-8 month, 2-drug cisplatin-containing regimen. <i>European Journal of Cancer &amp; Clinical Oncology</i> , <b>1987</b> , 23, 631-41		17
11	Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 741-751	3.5	12
10	Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 57-67	4.4	12
9	Pegylated liposomal doxorubicin and renal thrombotic microangiopathy: an under-recognized complication of prolonged treatment for ovarian cancer. <i>Kidney International</i> , <b>2014</b> , 85, 213	9.9	11
8	Sequential methotrexate and 5-fluorouracil with bleomycin and cisplatin in the chemotherapy of advanced squamous cancer of the head and neck. <i>Cancer</i> , <b>1986</b> , 57, 706-10	6.4	9
7	Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen Epitope. <i>American Journal of Pathology</i> , <b>2016</b> , 186, 1649-61	5.8	7
6	Bevacizumab in ovarian cancer: unanswered questions. <i>Drugs</i> , <b>2012</b> , 72, 931-6	12.1	6
5	Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS1124-TPS1124	2.2	3
4	Sequential therapy with INCAGN01949 followed by ipilimumab and nivolumab in two patients with advanced ovarian carcinoma. <i>Gynecologic Oncology Reports</i> , <b>2020</b> , 34, 100655	1.3	1
3	Medication-related osteonecrosis of the jaw: Evidence for infection versus oversuppression.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e18268-e18268	2.2	
2	Principles of Systemic Therapy <b>2009</b> , 27-40		
1	Platinum type is key in determining degree of neuropathy. <i>Gynecologic Oncology Reports</i> , <b>2018</b> , 26, 32	1.3	